ClearPoint Neuro's (CLPT) "Sell (D-)" Rating Reiterated at Weiss Ratings

Key Points

• Weiss Ratings has reiterated a "sell (D-)" rating for ClearPoint Neuro (NASDAQ:CLPT), highlighting ongoing concerns regarding the company's performance.
• Despite the negative rating from Weiss, the stock price has increased by 12.2% recently, reaching $29.60 with a current market capitalization of $841.53 million.
• Analysts indicate a mixed outlook with a consensus rating of "Moderate Buy" and a target price of $19.67, contrasting with some positive price target adjustments from Stifel Nicolaus.

ClearPoint Neuro (NASDAQ:CLPT - Get Free Report)'s stock had its "sell (d-)" rating reiterated by equities researchers at Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.

A number of other research analysts have also weighed in on the stock. Stifel Nicolaus raised their price target on shares of ClearPoint Neuro from $8.00 to $9.00 and gave the company a "buy" rating in a research note on Friday, August 1st. Wall Street Zen upgraded shares of ClearPoint Neuro from a "sell" rating to a "hold" rating in a report on Saturday, September 13th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, ClearPoint Neuro presently has a consensus rating of "Moderate Buy" and a consensus target price of $19.67.

ClearPoint Neuro Stock Up 12.2%

ClearPoint Neuro stock traded up $3.21 during midday trading on Wednesday, reaching $29.60. The stock had a trading volume of 1,331,006 shares, compared to its average volume of 1,583,342. The company has a market capitalization of $841.53 million, a P/E ratio of -36.54 and a beta of 1.19. The company has a current ratio of 7.30, a quick ratio of 6.45 and a debt-to-equity ratio of 1.46. ClearPoint Neuro has a 12 month low of $9.76 and a 12 month high of $29.87. The company has a fifty day moving average price of $13.63 and a two-hundred day moving average price of $12.73.

ClearPoint Neuro (NASDAQ:CLPT - Get Free Report) last posted its earnings results on Tuesday, August 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.01). ClearPoint Neuro had a negative return on equity of 94.44% and a negative net margin of 66.15%.The company had revenue of $9.22 million for the quarter, compared to analysts' expectations of $9.20 million. ClearPoint Neuro has set its FY 2025 guidance at EPS. As a group, equities analysts expect that ClearPoint Neuro will post -0.66 EPS for the current fiscal year.

Institutional Trading of ClearPoint Neuro

A number of hedge funds have recently bought and sold shares of the stock. Allworth Financial LP raised its holdings in shares of ClearPoint Neuro by 3,076.9% in the second quarter. Allworth Financial LP now owns 2,065 shares of the company's stock valued at $25,000 after purchasing an additional 2,000 shares during the last quarter. BNP Paribas Financial Markets increased its position in ClearPoint Neuro by 2,435.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,231 shares of the company's stock valued at $27,000 after purchasing an additional 2,143 shares during the period. Ameritas Investment Partners Inc. bought a new position in shares of ClearPoint Neuro during the 2nd quarter worth approximately $32,000. Legal & General Group Plc bought a new position in ClearPoint Neuro during the 2nd quarter valued at $35,000. Finally, PNC Financial Services Group Inc. purchased a new stake in shares of ClearPoint Neuro during the 2nd quarter valued at $48,000. 30.08% of the stock is owned by institutional investors.

About ClearPoint Neuro

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.